The Affordable Care Act has a major new element that will take effect soon.
Some major biotech companies in Massachusetts are unhappy with this development.
Boston Business Journal reporter Don Seiffer explains.
"This is marketing-related money, marketing and sales-related money, that a drug or device company would pay to a doctor or a hospital," said Seiffer. "[Companies] all say that transparency is good. However, they all say there's a stigma attached to this money that goes from industries to doctors."